ExThera Medical Corporation is developing revolutionary medical devices that address unmet clinical needs for the treatment of bloodstream infections and pathogen-reduction in blood banking.

The company was formed in 2008 through a joint venture between the Emergence Venture Partners Life Science Incubator and ExThera AB of Stockholm in 2008 and is currently conducting clinical studies of its first product, the Seraph® Microbind® Affinity Blood Filter.

The company is focused is on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations, but also intends to develop a device that prophylactically safeguards banked human blood.

Located in the San Francisco Bay area, the company is led by an experienced and seasoned management team, has a significant number of well-protected patents and a growing body of data from both company and independent laboratory conducted studies being used to advance Seraph toward clinical approval.


Blood Stream Infections are deadly:

  • 210,000 patients died from Sepsis (a Blood Stream Infection complication) in the US (2011), a mortality rate = 28%

Blood Stream Infections are expensive:

  • BSI/sepsis treatment account for over 40% of all Intensive Care Unit costs.

  • Drug-resistant infections could cost the global economy $100 trillion by 2050 (Fortune)

Blood Stream Infection incidence is growing:

  • Despite Pharmaceutical industry efforts, BSIs have continued to rise: by a factor of 3x since the 70’s.